Italian Sarcoma Group

Quick facts

Marketed products

• ADM · Oncology
  ADM (doxorubicin) is an anthracycline chemotherapy agent that intercalates into DNA and inhibits topoisomerase II, leading to DNA damage and cell death.
• CYC · Oncology
  CYC is a cyclophosphamide-based chemotherapy agent that alkylates DNA to inhibit cancer cell proliferation.
• ETO · Oncology
  ETO (etoposide) is a topoisomerase II inhibitor that prevents DNA religation, leading to DNA strand breaks and cell death.
• IFO · Oncology
  Ifosfamide is an alkylating agent that cross-links DNA, preventing cell replication and inducing apoptosis.
• VIN · Oncology
  VIN (vinblastine) is a vinca alkaloid that inhibits microtubule assembly by binding to tubulin, thereby disrupting cell division and inducing apoptosis in rapidly dividing cells.

Phase 3 pipeline

• Intensified chemotherapy · Oncology
  Intensified chemotherapy uses higher doses or more aggressive combinations of cytotoxic agents to maximize tumor cell kill in sarcoma patients.

Phase 2 pipeline

• BUMEL
• Mifamurtide arm
• TEMIRI

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Italian Sarcoma Group portfolio CI brief
• Italian Sarcoma Group pipeline updates RSS